1. Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial 
Carrie L. Kitko, Thomas Braun, Daniel R. Couriel, Sung W. Choi, James Connelly, Sandra Hoffmann, Steven Goldstein, John Magenau, Attaphol Pawarode, Pavan Reddy, Charles Schuler, Gregory A. Yanik, James L. Ferrara, John E. Levine 
Biology of Blood and Marrow Transplantation 
Volume 22, Issue 5, Pages (May 2016)
DOI: /j.bbmt
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1 Graft-versus-host disease prophylaxis schema.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
(A) Cumulative incidence of acute GVHD at day 100 was 46% (95% CI, 32% to 60%) and at day 180 was 57% (95% CI, 42% to 71%). (B) Cumulative incidence of steroid-refractory gastrointestinal GVHD at day 180 was 23% (95% CI, 13% to 38%). (C) Cumulative incidence of NRM at 1 year was 21% (95% CI, 14% to 27%) and at 2 years was 27% (95% CI, 14% to 40%). (D) Cumulative incidence of relapse at 1 year was 19% (95% CI, 8% to 30%) and at 2 years was 21% (95% CI, 9% to 32%). (E) Overall survival at 1 year was 73% (95% CI, 61% to 87%) and at 2 years was 56% (95% CI, 44% to 72%). (F) Cumulative incidence of chronic GVHD at 1 year was 42% (95% CI, 27% to 56%) and at 2 years was 58% (95% CI, 44% to 73%).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions